Lupus Research Alliance Grants Inaugural Awards to 11 Researchers Focused on Engineered Cell Therapies for Lupus
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on...
Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial
Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial
New York, NY. April 26, 2018. The Lupus Research Alliance today announced that the newly formed clinical affiliate Lupus Therapeutics will collaborate with the pharmaceutical company, Bristol-Myers Squibb (BMS), to conduct a global trial evaluating the novel investigational drug, BMS-986165, as a potential treatment for people with lupus.
BMS-986165 is a highly selective inhibitor of Tyrosine kinase 2 (Tyk2), which suppresses pathways that have been implicated in lupus.
